National recommendations for adult pneumococcal vaccination in countries of the WHO regions of Americas, Africa, Eastern Mediterranean, South East Asia, and Western Pacific.

Autor: Fletcher MA; Pfizer Vaccines and Antivirals, Medical and Scientific Affairs, Emerging Markets Region, France. Electronic address: mark.a.fletcher@pfizer.com., Vojicic J; Pfizer Vaccines and Antivirals, Medical and Scientific Affairs, Canada. Electronic address: jelena.vojicic@pfizer.com., Daigle D; Pfizer Vaccines and Antivirals, Medical and Scientific Affairs, Emerging Markets Region, USA. Electronic address: derek.daigle@pfizer.com., Taysi B; Pfizer Vaccines and Antivirals, Medical and Scientific Affairs, Emerging Markets Region, Singapore. Electronic address: bulent.taysi@pfizer.com., Haridy H; Pfizer Vaccines and Antivirals, Medical and Scientific Affairs, Emerging Markets Region, United Arab Emirates. Electronic address: hammam.haridy@pfizer.com., Abalos MG; Pfizer Vaccines and Antivirals, Medical and Scientific Affairs, Emerging Markets Region, Argentina. Electronic address: mariagabriela.abalos@pfizer.com., Del Carmen Morales G; Pfizer Vaccines and Antivirals, Medical and Scientific Affairs, Emerging Markets Region, USA. Electronic address: graciela.morales@pfizer.com.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2024 Dec 02; Vol. 42 (26), pp. 126390. Date of Electronic Publication: 2024 Sep 29.
DOI: 10.1016/j.vaccine.2024.126390
Abstrakt: Background: Adults who are elderly or who have underlying health conditions are at particular risk of Streptococcus pneumoniae infections, and pneumococcal vaccines are available. Nonetheless, only national recommendations from countries of North America and Europe have been previously reviewed in the literature.
Methods: Consequently, we aimed to collate national guidelines for adult pneumococcal immunization across the 161 countries within the World Health Organization (WHO) regions-the Americas (except Canada and the United States of America), Africa, Eastern Mediterranean, South East Asia, and Western Pacific-from country-level official websites and documents, from the WHO portal, and from direct contact with public health officials, pertinent governmental sources, or local vaccination experts.
Results: For 40.4 % (65/161) of these countries, adult pneumococcal vaccination information was available. Among these 65 with available information, 63.1 % (41/65) include adult pneumococcal vaccination in the national vaccination schedule: 58.5 % (24/41) recommend vaccination both for older adults and for risk groups, while 9.8 % (4/41) recommend it only for older adults, and 31.7 % (13/41) only for risk groups. Of note, among the 13 national risk based-only recommendations, 30.8 % (4/13) are age-dependent and strictly reserved for older adults. The regions where age-based adult pneumococcal vaccination recommendations seem to predominate are South East Asia, Western Pacific, and the Americas. The threshold for age-based pneumococcal vaccination recommendations varies between 50 and 70 years of age. The Americas has the highest proportion of countries with risk-based recommendations. Three-quarters of these countries include PCV and PPV23 in the recommendations, most often given in sequence.
Conclusions: Less than half of countries of the five WHO regions analyzed have accessible information on adult pneumococcal vaccination, and only 25.5 % (41/161) of all countries reviewed recommend adult pneumococcal immunization within the national vaccination schedule. Policymakers should consider extending pneumococcal vaccination guidelines-adapted to national priorities for adult healthcare-as based on local age demographics and risk factor predominance.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Mark A Fletcher reports financial support was provided by Pfizer. Jelena Vojicic reports financial support was provided by Pfizer. Derek Daigle reports financial support was provided by Pfizer. Bulent Taysi reports financial support was provided by Pfizer. Hammam Haridy reports financial support was provided by Pfizer. Maria Gabriela Abalos reports financial support was provided by Pfizer. Graciela del Carmen Morales reports financial support was provided by Pfizer. Mark A Fletcher reports a relationship with Pfizer that includes: equity or stocks. Jelena Vojicic reports a relationship with Pfizer that includes: equity or stocks. Derek Daigle reports a relationship with Pfizer that includes: equity or stocks. Hammam Haridy reports a relationship with Pfizer that includes: equity or stocks. Maria Gabriela Abalos reports a relationship with Pfizer that includes: equity or stocks. Graciela del Carmen Morales reports a relationship with Pfizer that includes: equity or stocks. MAF, JV, DD, BT, HH, MGA, and GdCM are employees of Pfizer Inc. and may hold stock or stock options. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. MAF, JV, DD, BT, HH, MGA, and GdCM are employees of Pfizer Inc. and may hold stock or stock options.
(Copyright © 2024 Pfizer, Inc. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: